Loading cancer entity…
Loading cancer entity…
Clinical trials
296 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (43)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT02515110 | Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer | active not recruiting | N/A | 137 | Virginia Commonwealth UniversityOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT04457596 | T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial | active not recruiting | Phase 3 | 1,056 | Alliance for Clinical Trials in OncologyOTHER | 3 | Jun 15, 2026 | clinicaltrials |
| NCT07474090 | Personalized Exercise Program for Survivors of Breast Cancer, STEPS-BC Trial(STEPS-BC) | recruiting | N/A | 120 | Wake Forest University Health SciencesOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT06763328 | Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing Chemotherapy | recruiting | Phase 3 | 80 | City of Hope Medical CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT02971748 | Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy | active not recruiting | Phase 2 | 36 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT03202316 | Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer | active not recruiting | Phase 2 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07635654 | Disease Extent in Stage IV Lobular Carcinoma: the Aid of Imaging and Liquid Biopsy Analyses(DELILA) | not yet recruiting | N/A | 43 | KU LeuvenOTHER | 0 | Jun 9, 2026 | clinicaltrials |
| NCT01953588 | Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery | active not recruiting | Phase 3 | 1,473 | Alliance for Clinical Trials in OncologyOTHER | 2 | Jun 5, 2026 | clinicaltrials |
| NCT03737695 | Clinical Information and Biospecimen Collection From Patients With Recurrent or Stage IV Breast Cancer | active not recruiting | — | 300 | Mayo ClinicOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT05660083 | Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC) | recruiting | Phase 2 | 36 | The Methodist Hospital Research InstituteOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT05786664 | Breast Cancer Survivorship Biorepository | recruiting | — | 1,300 | University of Southern CaliforniaOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT03941756 | Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma | recruiting | N/A | 252 | M.D. Anderson Cancer CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT04648904 | Study of a Shortened Radiation Therapy Schedule in People With Breast Cancer | active not recruiting | Early Phase 1 | 71 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT00877500 | Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy | active not recruiting | Phase 2 | 116 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04622319 | A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) | active not recruiting | Phase 3 | 1,600 | Daiichi SankyoINDUSTRY | 31 | May 15, 2026 | clinicaltrials |
| NCT04314401 | National Cancer Institute "Cancer Moonshot Biobank" | active not recruiting | — | 1,600 | National Cancer Institute (NCI)NIH | 2 | May 13, 2026 | clinicaltrials |
| NCT07475325 | Individual Factors Associated With Care Pathways Delays in Breast Cancer in Hauts-de-France.(E-C-HAU) | active not recruiting | — | 500 | University Hospital, LilleOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT05319873 | Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 18 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT04647916 | Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases | active not recruiting | Phase 2 | 44 | SWOG Cancer Research NetworkNETWORK | 1 | May 6, 2026 | clinicaltrials |
| NCT05406232 | Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer | recruiting | — | 36 | M.D. Anderson Cancer CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07555210 | Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy | recruiting | N/A | 25 | Jessica Mezzanotte SharpeOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT04169542 | Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery | recruiting | — | 600 | M.D. Anderson Cancer CenterOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT01245712 | Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer | active not recruiting | Phase 2 | 200 | M.D. Anderson Cancer CenterOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07544134 | Areola Preservation in NSM With Nipple Involvement(APRESERVE-1) | not yet recruiting | N/A | 40 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT03971409 | Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer(InCITe) | active not recruiting | Phase 2 | 145 | Laura Huppert, MD, BAOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT02918474 | Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer | recruiting | N/A | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT00477100 | Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer | recruiting | — | 1,200 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT02876107 | Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer | active not recruiting | Phase 2 | 42 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06638931 | Agnostic Therapy in Rare Solid Tumors(ANTARES) | recruiting | Phase 2 | 28 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07527468 | HISMAR: Intraoperative Margin Assessment Using the Histolog® Scanner to Reduce Reoperation in Breast-Conserving Surgery(HISMAR) | not yet recruiting | N/A | 228 | Hôpital du ValaisOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT04569747 | A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer(ADEPT) | active not recruiting | Phase 2 | 393 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT07289282 | Circulating microRNAs and Response to Neoadjuvant Chemotherapy in Breast Cancer(miRNA-NAC) | recruiting | — | 80 | Atlas UniversityOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT01525966 | Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer | active not recruiting | Phase 2 | 67 | City of Hope Medical CenterOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07500129 | Tissue- and Serum-Derived Exosomal microRNAs as Predictors of Neoadjuvant Chemotherapy Response in Breast Cancer(ExoTSS-BC) | not yet recruiting | — | 60 | Atlas UniversityOTHER | 0 | Mar 30, 2026 | clinicaltrials |
| NCT05318274 | Hypofractionated Radiation Therapy vs Standard Treatment in Breast Cancer. | active not recruiting | N/A | 72 | Coordinación de Investigación en Salud, MexicoOTHER_GOV | 1 | Mar 23, 2026 | clinicaltrials |
| NCT06268665 | Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy | recruiting | Phase 2 | 86 | University of California, DavisOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT04897009 | Impact of Neoadjuvant Chemotherapy on the Peripheral Blood Immune Phenotype in Operable Breast Cancer(ENHANCE) | active not recruiting | — | 38 | Mayo ClinicOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT03414970 | Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer | active not recruiting | Phase 3 | 898 | Alliance for Clinical Trials in OncologyOTHER | 2 | Feb 24, 2026 | clinicaltrials |
| NCT07421479 | Patient-Derived Breast Cancer Organoids for Therapeutic Extracellular Vesicle Isolation (PDO-Mercurial01)(PDO-Mercurial) | active not recruiting | — | 50 | Istituti Clinici Scientifici Maugeri SpAOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT06744465 | NearWave Optical Molecular Monitoring | recruiting | N/A | 15 | Indiana UniversityOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT05383196 | Onvansertib + Paclitaxel In TNBC | active not recruiting | Phase 1 / Phase 2 | 50 | Antonio Giordano, MDOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT04368702 | CONFIRM: Magnetic Resonance Guided Radiation Therapy(CONFIRM) | recruiting | N/A | 70 | Brigham and Women's HospitalOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT04959474 | Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer | recruiting | N/A | 80 | Thomas Jefferson UniversityOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT04871516 | Radiation Therapy Boost Before Surgery for the Treatment of Non-metastatic Breast Cancer | active not recruiting | N/A | 103 | Rutgers, The State University of New JerseyOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT05693766 | Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort(INSIGHT) | recruiting | Phase 2 | 64 | Sonya ReidOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT06666439 | Longitudinal Tumor Burden Quantification Using Circulating Tumor DNA in Metastatic Lobular Breast Cancer(LBC-Monitor) | recruiting | — | 20 | Julia FoldiOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT04448886 | Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC | active not recruiting | Phase 2 | 110 | Ana C Garrido-Castro, MDOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT06328465 | fREEDOM: REsonance for Early Detection Of Breast Cancer Metastases(fREEDOM) | recruiting | N/A | 145 | European Institute of OncologyOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT07080944 | Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in IBC(SYMPHONY) | recruiting | N/A | 75 | European Institute of OncologyOTHER | 1 | Jan 6, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jun 17, 2026source: clinicaltrials